Mainz Biomed Announces First Quarter 2023 Financial Results and Provides Corporate Update
ColoAlert® Revenue Increases
BERKELEY, Calif. and MAINZ, Germany, May 16, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today first quarter results which ended March 31, 2023 and provided a corporate update.
Key Highlights During Q1 2023
- ColoAlert® revenues were USD 250,077, representing an increase of
152% compared to Q1 2022 - Expanded the international commercialization for ColoAlert, Mainz Biomed’s highly efficacious and easy-to-use DNA-based detection test for colorectal cancer (CRC) being sold via the Company’s unique business model of marketing products via partnerships with third-party laboratories versus the traditional methodology of operating a single facility
- Grew network of laboratory partnerships across Europe with additions in Germany, Spain and England
- Launched corporate health program in Germany accessing a
EURO 1 billion annual market - Integration into Country’s “BGM” system providing employee health services - U.S. Pivotal Clinical Trial (ReconAAsense) remains on track to commence patient enrollment in 2H 2023 – Opportunity to achieve gold standard status for self-administered CRC screening
- Exercised exclusive option with Uni Targeting Research AS to acquire all of the previously licensed scientific IP for ColoAlert
- Acquired entire IP portfolio for family of novel gene expression (mRNA) biomarkers from Sciences Sante et Humaines S.E.C. (“SOCPRA”) that demonstrated ability to detect CRC lesions, including advanced adenomas (“AA”), a type of pre-cancerous polyp often attributed to CRC
- Continued executing European and U.S. clinical studies (ColoFuture/eAArly DETECT) evaluating the SOCPRA biomarker portfolio for potential inclusion in ReconAAsense - eAArly DETECT on track to report results in mid-2023 & ColoFuture’s readout is expected in H2 2023.
- Maintained development pace for pipeline asset PancAlert, a potential first-in-class screening test for pancreatic cancer
“The first quarter of 2023 proved to be a remarkable period of progress as we continue to build-out ColoAlert’s commercial franchise across Europe while executing on our programs in development, highlighted by the commencement of patient enrollment in the U.S. pivotal study for our CRC test by end of year,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “As we prepare for this milestone, we eagerly await the results from the eAArly DETECT clinical trial which if successful, will integrate biomarkers from the SOCPRA portfolio into ReconAAsense, representing the opportunity to bring to market a disruptive, groundbreaking CRC screening solution for early stage disease detection and prevention.”
Commercial Update: Broadened ColoAlert’s commercial reach in key European markets
During the quarter, Mainz Biomed continued ColoAlert’s European commercial roll-out by establishing partnerships with Marylebone Laboratory (Marylebone Lab LTD) and Instituto de Microecologia, two leading independent laboratories covering England, Spain and Portugal. The addressable market in Spain is estimated at 26 million patients and at 9 million patients in the greater London region. In Germany, Mainz Biomed expanded ColoAlert’s availability in the country through a partnership with Dr Staber & Kollegen GmbH (Labor Staber), and the launch of a corporate health program focused on companies across the country, representing a
Product Development Update: ReconAAsense U.S. pivotal clinical trial, ColoFuture/eAArly DETECT clinical studies & pancreatic test advancements
Throughout the first quarter, Mainz Biomed continued to prepare for commencing patient enrollment in the ReconAAsense study (ClinicalTrials.gov Identifier: NCT05636085) in H2 2023. This U.S. pivotal clinical trial assessing Mainz Biomed’s CRC test will form the basis of the data package for review by the U.S. Food and Drug Administration (FDA) to achieve marketing authorization. It will include approximately 15,000 subjects from 150 sites across the U.S., and study’s primary objectives include calculating sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) in average-risk subjects for CRC and AA. Additionally, Mainz Biomed continued executing its ColoFuture (Europe) and eAArly DETECT (U.S.) studies evaluating the Company’s proprietary portfolio of novel gene expression (mRNA) biomarkers for possible inclusion in the ReconAAsense trial because they have previously demonstrated ability to detect CRC lesions, including AA, a type of pre-cancerous polyp often attributed to this deadly disease.
The eAArly DETECT clinical trial, which commenced enrollment in December of 2022, remains on track to report results in mid-2023. The multi-center feasibility study is enrolling 250 subjects across 25 sites in the U.S.. The international multi-center ColoFuture study continued enrolling patients in Europe (recruiting over 600 patients in the age range of 40-85) with results expected in H2 2023. If any of the biomarkers are integrated into the ReconAAsense trial and the study produces positive results, this next iteration of Mainz Biomed’s CRC test will be positioned as the most robust and accurate at-home diagnostic screening solution on the market, as it will not only detect cancerous polyps with a high degree of accuracy but has the potential to prevent CRC through early detection of precancerous adenomas. To this end, a promising research milestone was achieved during the quarter when Mainz Biomed announced positive results from an independent feasibility study conducted in collaboration with members of the Early Detection Research Network (EDRN) to evaluate the same portfolio of gene expression biomarkers. Key findings included Mainz Biomed’s proprietary nucleic acid extraction and PCR process proved to be highly effective, and two of the mRNA biomarkers were found to be particularly valuable in detecting disease signals in advanced adenoma samples.
During the quarter, Mainz Biomed continued to conduct pre-clinical work on PancAlert, the Company’s novel and potential first-in-class early detection test for pancreatic cancer, a malignant neoplasm of the pancreas with one of the highest mortality rates of all major cancers. In fact, a recent highlight (May 10th, 2023) was the establishment of a research partnership with Microba Life Sciences (ASX: MAP), a precision microbiome company that is built around a unique metagenomic platform technology with the ability to produce comprehensive and accurate species profiles of human gastrointestinal samples. The collaboration will focus on leveraging this sequencing technology and bioinformatic tool to potentially discover novel microbiome biomarkers for pancreatic cancer detection for integration into PancAlert’s technical configuration.
Corporate Update: Acquired entire IP portfolio for colorectal cancer program
A major corporate growth milestone achieved during the first quarter was executing the Company’s option from Uni Targeting Research AS to acquire all of the previously licensed scientific intellectual property (“IP”) for ColoAlert. In addition and in synchronicity with this transaction, Mainz Biomed exercised its exclusive option with SOCPRA Sciences Sante et Humaines S.E.C. to outright purchase all of the IP, including a pending patent associated with the portfolio of novel gene expression (mRNA) biomarkers that are being evaluated in the ColoFuture/eAArly DETECT studies, and which may be integrated into the ReconAAsense pivotal trial. Securing complete IP ownership of these assets is a significant value generating milestone for Mainz Biomed as it streamlines administration, reduces per-test expenses, and provides the opportunity to ramp-up corporate development activities.
CONDENSED CONSOLIDATED FINANCIAL INFORMATION
During the three months ended March 31, 2023 the Company saw its revenue from ColoAlert grow
The Company has filed a current report on Form 6-K on May 16, 2023, with the U.S. Securities and Exchange Commission, which includes both consolidated financial statements and management’s discussion and analysis of its financial results for the first quarter of 2023. Summary financial tables are included below.
| Mainz Biomed N.V. | |||||||
| Condensed Statements of Profit or Loss and Other Comprehensive Loss (unaudited) | |||||||
| Three months ended | |||||||
| March 31, | |||||||
| 2023 | 2022 | ||||||
| Revenue | |||||||
| ColoAlert Revenue | $ | 250.077 | $ | 99.051 | |||
| Other Revenue | 27 | 1.514 | |||||
| Total Revenue | 250.104 | 100.565 | |||||
| Cost of sales | 111.163 | 54.136 | |||||
| Gross profit | 138.941 | 46.429 | |||||
| Gross margin | |||||||
| Operating expenses: | |||||||
| Sales and marketing | 2.410.935 | 921.630 | |||||
| Research and development | 2.625.072 | 563.572 | |||||
| General and administrative | 1.590.490 | 4.192.785 | |||||
| Total operating expenses | 6.626.497 | 5.677.987 | |||||
| Loss from operations | (6.487.556) | (5.631.558) | |||||
| Other expense | (73.360) | (32.178) | |||||
| Income (loss) before income tax | (6.560.916) | (5.663.736) | |||||
| Income taxes provision | - | - | |||||
| Net loss | $ | (6.560.916) | $ | (5.663.736) | |||
| Foreign currency translation gain (loss) | (60.572) | 36.439 | |||||
| Comprehensive loss | $ | (6.621.488) | $ | (5.627.297) | |||
| Basic and dilutive loss per ordinary share | $ | (0,45) | $ | (0,42) | |||
| Weighted average number of ordinary shares outstanding | 14.688.361 | 13.348.349 | |||||
| Mainz Biomed N.V. | |||||||
| Condensed Statements of Profit or Loss and Other Comprehensive Loss (unaudited) | |||||||
| Three months ended | |||||||
| March 31, | |||||||
| 2023 | 2022 | ||||||
| Revenue | |||||||
| ColoAlert Revenue | $ | 250.077 | $ | 99.051 | |||
| Other Revenue | 27 | 1.514 | |||||
| Total Revenue | 250.104 | 100.565 | |||||
| Cost of sales | 111.163 | 54.136 | |||||
| Gross profit | 138.941 | 46.429 | |||||
| Gross margin | |||||||
| Operating expenses: | |||||||
| Sales and marketing | 2.410.935 | 921.630 | |||||
| Research and development | 2.625.072 | 563.572 | |||||
| General and administrative | 1.590.490 | 4.192.785 | |||||
| Total operating expenses | 6.626.497 | 5.677.987 | |||||
| Loss from operations | (6.487.556) | (5.631.558) | |||||
| Other expense | (73.360) | (32.178) | |||||
| Income (loss) before income tax | (6.560.916) | (5.663.736) | |||||
| Income taxes provision | - | - | |||||
| Net loss | $ | (6.560.916) | $ | (5.663.736) | |||
| Foreign currency translation gain (loss) | (60.572) | 36.439 | |||||
| Comprehensive loss | $ | (6.621.488) | $ | (5.627.297) | |||
| Basic and dilutive loss per ordinary share | $ | (0,45) | $ | (0,42) | |||
| Weighted average number of ordinary shares outstanding | 14.688.361 | 13.348.349 | |||||
About Mainz Biomed NV
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. ColoAlert is currently marketed across Europe. The Company is running a pivotal FDA clinical study for US regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test. To learn more, visit mainzbiomed.com or follow us on LinkedIn, Twitter and Facebook.
For media inquiries, please contact press@mainzbiomed.com
In Europe:
MC Services AG
Anne Hennecke/Caroline Bergmann
+49 211 529252 20
mainzbiomed@mc-services.eu
In the US:
Spectrum Science
Melissa Laverty/Valerie Enes
+1 540 272 6465
mainz@spectrumscience.com
For investor inquiries, please contact info@mainzbiomed.com
Forward-Looking Statements
Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on May 5, 2022. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.
